Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
PF-07220060 + PF-07104091 combination dose escalation Phase 2 Results Expected
PF-07220060 + PF-07104091 combination dose escalation • Breast Cancer
Target Indication
Breast Cancer
Clinical Trial
NCT05262400Last updated: 12/18/2025